KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Operating Leases (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Operating Leases for 6 consecutive years, with $137.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases rose 106.8% year-over-year to $137.1 million, compared with a TTM value of $137.1 million through Sep 2025, up 106.8%, and an annual FY2024 reading of $65.4 million, down 8.22% over the prior year.
  • Operating Leases was $137.1 million for Q3 2025 at AbCellera Biologics, roughly flat from $137.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $137.2 million in Q2 2025 and bottomed at $17.0 million in Q1 2021.
  • Average Operating Leases over 5 years is $65.0 million, with a median of $66.5 million recorded in 2024.
  • The sharpest move saw Operating Leases soared 880.16% in 2021, then fell 14.89% in 2024.
  • Year by year, Operating Leases stood at $36.4 million in 2021, then soared by 110.57% to $76.7 million in 2022, then fell by 7.11% to $71.2 million in 2023, then fell by 8.22% to $65.4 million in 2024, then skyrocketed by 109.68% to $137.1 million in 2025.
  • Business Quant data shows Operating Leases for ABCL at $137.1 million in Q3 2025, $137.2 million in Q2 2025, and $63.2 million in Q1 2025.